Replies to post #249932 on Biotech Values

[Whalatane]

Mufaso /Jbog ...thx for the interesting discussion and the DD you both provide .
P2 data for VENTURE VK2735 late Q2 2024 ...that will be huge .
Small long position
Dew ...Thx for maintaining such a quality board for biotech investors
Kiwi

[north40000]

We like VKTX also….our holdings were purchased at end of November 2022, so we currently have a LTCG.

AVXL is reported to have filed an application in EU, naming AD and perhaps Retts and Parkinson’s as indication(s) to be treated with Blarcasimine(sp?).

The Phase 3 BRAVE trial of Amarin’s Vascepa, orally dosed in cognitively healthy adults at 4 gms/day, completed 9/29/2023. Dr. Cynthia Carlsson, U. Wisconsin, is P.I. It appears top-line results may be reported this year, and full results by end of March 2024. https://reporter.nih.gov/project-details/9031632 has further description when all links are clicked.